Allergan’s TrueTear Intranasal Team Neurostimulator is designed to temporarily increase tear production in adults. (PRNewsfoto/Allergan plc).
DUBLIN—The U.S. Food and Drug Administration (FDA) has granted Allergan (NYSE: AGN) marketing authorization for a pocket-sized device designed to temporarily increase tear production in adults.

Allergan described the device, known as the TrueTear Intranasal Tear Neurostimulator, as “a handheld stimulator with daily disposable tips that is inserted into the nasal cavity to induce the production of tears.” Allergan reported that there have been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.

“TrueTear represents a technological breakthrough for eyecare professionals as it delivers an effective, non-invasive and drug-free way to temporarily increase tear production,” said David Nicholson, chief R&D officer, at Allergan. "As an innovator in eyecare, we are continually looking for new products to offer through our portfolio, and TrueTear represents the next step forward.”